^
Association details:
| Biomarker: | TP53 mutation |
|---|---|
| Cancer: | Chronic Lymphocytic Leukemia |
| Drug: | Imbruvica (ibrutinib) (BTK inhibitor) + Breyanzi (lisocabtagene maraleucel) (CD19-targeted CAR-T immunotherapy) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
086 | TRANSCEND CLL 004: PHASE 1 COHORT OF LISOCABTAGENE MARALEUCEL (LISO-CEL) COMBINED WITH IBRUTINIB (IBR) FOR PATIENTS (PTS) WITH R/R CLL/SLL
Published date:
06/09/2021
Excerpt:
Eligible pts with R/R CLL/SLL...19 pts received liso-cel (DL1, n = 4; DL2, n = 15) with ibr....18 pts (95%) had high-risk cytogenetics (del[17p], n = 8; TP53 mutation, n = 6; complex karyotype [≥3 chromosomal aberrations], n = 8)....Of 19 pts with ≥1-mo follow-up, 18 (95%) had an objective response; 12 (63%) had a CR/CRi. One pt (5%) had stable disease...and 16 of 18 pts (89%) have ongoing responses at ≥6 mo.
Trial ID:
